title: Melioidosis: advances in diagnosis and treatment.
abstract: OBJECTIVE
  Melioidosis is an infectious disease caused by the soil-associated Gram-negative bacterium Burkholderia pseudomallei. This review summarizes the evidence underlying current antibiotic regimens and discusses future strategies to reduce mortality.
  
  
  RESULTS
  Although simple rapid diagnostics exist, they rely on the availability of direct specimen and are not commercially available. Serological tests and nucleic acid detection are not sufficiently specific or sensitive for routine clinical use. Since the original trials defining setting the standard of care as ceftazidime, no antibiotic regimens have been shown to be superior in comparative trials, but ongoing trials are evaluating the efficacy of meropenem (in intensive treatment) and (TMP-SMX) (for eradication treatment).
  
  
  CONCLUSIONS
  In endemic areas, empiric antibiotics should include agents active against melioidosis as well as the other common causes of severe sepsis. It is likely that future improvements in mortality will be the result of efforts to improve on the early recognition and management of severe sepsis generally.
authors.affiliation: Department of Epidemiology and Preventive Medicine, Monash University, Infectious Diseases Unit, Alfred Hospital, Melbourne, Victoria, Australia. allen.cheng@monash.edu.au
authors.forename: Allen C
authors.initials: AC
authors.lastname: Cheng
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D016957:Burkholderia pseudomallei / Q000187:drug effects* / Q000472:pathogenicity; D002442:Ceftazidime / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D019317:Evidence-Based Medicine; D006801:Humans; D008554:Melioidosis / Q000175:diagnosis* / Q000188:drug therapy* / Q000401:mortality; D000077731:Meropenem; D012680:Sensitivity and Specificity; D018805:Sepsis / Q000175:diagnosis* / Q000188:drug therapy* / Q000401:mortality; D013845:Thienamycins / Q000627:therapeutic use; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D013845:Thienamycins; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D002442:Ceftazidime; D000077731:Meropenem